Literature DB >> 21709542

Amino acid substitutions in the hepatitis C virus core region are associated with postoperative recurrence and survival of patients with HCV genotype 1b-associated hepatocellular carcinoma.

Hidenori Toyoda1, Takashi Kumada, Yuji Kaneoka, Atsuyuki Maeda.   

Abstract

OBJECTIVE: We researched the molecular marker for prognosis of postoperative patients with hepatocellular carcinoma (HCC).
BACKGROUND: The association of amino acid substitutions in the hepatitis C virus (HCV) core region and hepatocarcinogenesis has recently been explored. We investigated if these amino acid substitutions are associated with recurrence or survival in patients with HCC after attempted curative treatment by hepatectomy.
METHODS: A total of 163 patients infected with HCV genotype 1b who previously underwent hepatectomy for primary, not recurrent HCC were analyzed. Amino acid substitutions in the HCV core region were measured by direct sequencing. Postoperative recurrence or survival rates were compared according to tumor characteristics, tumor markers, and amino acid substitutions in the core region.
RESULTS: Recurrence rates after hepatectomy were higher in patients bearing a methionine at residue 91 of the HCV core region than in patients with leucine (P = 0.0002). Survival was also decreased in patients with methionine at this residue from that seen in patients with leucine at this position (P = 0.0061). The associations between amino acid substitutions at residue 91 of the HCV core region and either recurrence or survival rates were independent of liver function, progression of HCC, or tumor marker levels.
CONCLUSIONS: Amino acid substitutions at residue 91 of the HCV core region are associated with postoperative recurrence or survival in patients infected with HCV genotype 1b who developed HCC and treated by hepatectomy. This factor should be taken into consideration for the postoperative management of patients with HCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21709542     DOI: 10.1097/SLA.0b013e3182263b8e

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  7 in total

1.  Genotypic Regulation of Type I Interferon Induction Pathways by Frameshift (F) Proteins of Hepatitis C Virus.

Authors:  Yi-Ting Lai; Yih-Mei Liou; Fu Hsin; Helene Minyi Liu
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

Review 2.  Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma.

Authors:  Virginia Sedeno-Monge; Veronica Vallejo-Ruiz; Francisca Sosa-Jurado; Gerardo Santos-Lopez
Journal:  J Biosci       Date:  2017-09       Impact factor: 1.826

3.  A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene.

Authors:  Ahmed El-Shamy; Francis J Eng; Erin H Doyle; Arielle L Klepper; Xiaochen Sun; Angelo Sangiovanni; Massimo Iavarone; Massimo Colombo; Robert E Schwartz; Yujin Hoshida; Andrea D Branch
Journal:  J Hepatol       Date:  2015-07-26       Impact factor: 25.083

4.  Challenges of incorporating gene expression data to predict HCC prognosis in the age of systems biology.

Authors:  Yan Du; Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

5.  Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation.

Authors:  Yan Du; Tong Su; Yibo Ding; Guangwen Cao
Journal:  Hepat Mon       Date:  2012-10-20       Impact factor: 0.660

6.  Clinical significance of occult hepatitis B infection in progression of liver disease and carcinogenesis.

Authors:  Hiroki Nishikawa; Yukio Osaki
Journal:  J Cancer       Date:  2013-07-11       Impact factor: 4.207

7.  Impact of HCV core gene quasispecies on hepatocellular carcinoma risk among HALT-C trial patients.

Authors:  Ahmed El-Shamy; Matthew Pendleton; Francis J Eng; Erin H Doyle; Ali Bashir; Andrea D Branch
Journal:  Sci Rep       Date:  2016-06-01       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.